Last reviewed · How we verify
RD14-01 Cell injection
RD14-01 Cell injection is a Small molecule drug developed by Shen Lin. It is currently in Phase 1 development.
At a glance
| Generic name | RD14-01 Cell injection |
|---|---|
| Sponsor | Shen Lin |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RD14-01 in Patients With Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RD14-01 Cell injection CI brief — competitive landscape report
- RD14-01 Cell injection updates RSS · CI watch RSS
- Shen Lin portfolio CI
Frequently asked questions about RD14-01 Cell injection
What is RD14-01 Cell injection?
RD14-01 Cell injection is a Small molecule drug developed by Shen Lin.
Who makes RD14-01 Cell injection?
RD14-01 Cell injection is developed by Shen Lin (see full Shen Lin pipeline at /company/shen-lin).
What development phase is RD14-01 Cell injection in?
RD14-01 Cell injection is in Phase 1.
Related
- Manufacturer: Shen Lin — full pipeline
- Compare: RD14-01 Cell injection vs similar drugs
- Pricing: RD14-01 Cell injection cost, discount & access